Technical bottlenecks in the analysis of clonal hematopoiesis and mosaic chromosomal alterations (mCA) Clonal hematopoiesis (CH), in which a subset of blood cells acquires somatic mutations and expands excessively, is a key driver not only of hematologic malignancies such as leukemia but also of a dramatic increase in cardiovascular disease risk. The phenomenon is underpinned by mosaic chromosomal alterations (mCA) that arise during cell division. Conventional microarray or low‑resolution sequencing approaches lack the precision to detect mCAs that exist at very low cell fractions within a cell population. In particular, structural variants known as copy‑neutral loss‑of‑heterozygosity (cnLOH), which preserve total copy number while replacing one parental haplotype with the other, have remained a major unsolved problem in genomics: it has been unclear which genetic drivers trigger clonal expansion via cnLOH.

Re‑analysis of UK Biobank WGS: discovery of 43,617 mCAs and genetic links to cnLOH The research team re‑processed raw whole‑genome sequencing (WGS) data from hundreds of thousands of UK Biobank participants using a custom ultra‑high‑resolution algorithm pipeline. This effort uncovered 43,617 previously missed fine‑scale mosaic variants. Molecular dynamics analysis revealed that cnLOH events are not random; they show a striking statistical association with ultra‑rare protein‑coding variants and tend to cluster on specific chromosomal trajectories, establishing a novel genetic rule.

Bias toward loss‑of‑function (LoF) variants and the dynamics of clonal expansion A mechanistic breakthrough of the study is the demonstration that certain rare coding variants impair gene metabolic or tumor‑suppressor functions, creating loss‑of‑function (LoF) alleles. For example, a hematopoietic stem cell carrying an LoF allele on one chromosome can, through somatic recombination, lose the wild‑type allele and duplicate the mutant allele via cnLOH. The resulting cell lacks tumor‑suppressor protection and gains unchecked clonal expansion capacity. This provides clear causal evidence of how selective fitness advantages in hematopoietic cells are genetically programmed.

Filtering false cancer signals and optimizing precision liquid‑biopsy algorithms The impact of this work on genomic medicine and diagnostic biotech lies in redefining the criteria for false‑positive/false‑negative calls in blood‑based liquid‑biopsy and early‑cancer detection platforms. Previously, cnLOH or mCA detected in blood were treated as mere aging by‑products or random noise, precluding quantitative risk assessment. By establishing a combined model of rare coding variants and cnLOH using large‑scale WGS data, clinicians can now generate ultra‑precise risk scores for progression to overt hematologic malignancy or myelodysplastic syndrome (MDS) from a simple blood draw. This model constitutes a unique data asset that can serve as the core filtering engine in clinical diagnostic pipelines.